Additionally, the integration of novel pharmacotherapeutic agents such as SGLT2 inhibitors and sacubitril/valsartan in the treatment regimen for heart failure holds promise for ameliorating sleep parameters in patients with OSA + HF. The gene discussed is SLC5A2; the disease is obstructive sleep apnea syndrome.